Our collaborative paper is finally out in Immunity! Please check out the great Tweetorial posted by co-first author Olli Dufva to learn more about NK and blood cancer cells interactions.

Very proud to be part of such an amazing collaboration between HRUH hematology and CMitsiadesLab, to share the leading authorship with Olli Dufva and to have the best coauthors. Check out our paper, now out in Immunity

cell.com/immunity/fullt…

Very proud to share latest work from Constantine Mitsiades lab, started during my time at Dana-Farber / Harvard Medical School .

nature.com/articles/s4301…

A new study published in Nature Cancer led by CMitsiadesLab at @danafarber uses CRISPR to identify more than 100 genes as potential leads for the discovery of new drugs for multiple myeloma.
Full release ➡️ ms.spr.ly/6010gjNMg
#mmsm #myeloma #CRISPR

Time to wake up the potential of NK-directed therapy in #myeloma . Sara Gandolfi showing compelling data to pique our interest. #IMS 2022 #IMS

The results of our work are finally out on bioRxiv! A huge collaborative effort between HRUH hematology and CMitsiadesLab with co-first author Olli Dufva, to define the interaction of NK cells and blood cancer cells. Check it out

Excited to share our new work on NK cells. Fantastic work by Olli Dufva & Sara Gandolfi, team members from our lab Medicine and Health, University of Helsinki & CMitsiadesLab Dana-Farber News and many collaborators. Fascinating to see how different cancer cells impact NK cell responses biorxiv.org/content/10.110…

We finally tested how knocking out CRISPR hits in cancer cells influences NK cells. This gave some interesting results, such as defective activation with CD58 knockout and increased activation with JAK1 knockout.

18/